

2009 Cancer Data Summary

Incidence of Cancer 2009

In 2009, 3,809 new cancer cases were accessioned into the NorthShore University HealthSystem (NorthShore) Cancer Registry. Of those, 3,344 cases (88 percent) were analytic. By definition, analytic cases are those patients newly diagnosed with malignant neoplasm and/or have received all or part of their first course of treatment at one of our Hospitals. The remaining 465 cases (12 percent) were non-analytic. Non-analytic cases are patients initially diagnosed and treated at another facility, who now are receiving treatment for progression or recurrence of their disease at NorthShore. Details by site are provided in Table 1.

Class of Case 2009

Class 0, 1 and 2 are considered analytic cases; Class 3, 4, 5, 6 and 7 are non-analytic.

Class 0 and Class 1, which account for 2,759 cases, were those malignancies diagnosed at one of our four Hospitals. Once diagnosed with cancer, 2,644 (96 percent) of our patients remained at NorthShore for their treatment. Class 2, totaling 585 cases, were diagnosed elsewhere and referred to NorthShore for treatment. Class 3, a total of 418 cases were diagnosed and treated elsewhere and referred here for treatment of a recurrence or progression of disease. The remaining 47 cases are divided among other non-analytic classes.

Overall Top 5 NorthShore Sites

Breast cancer continues to be our top cancer site representing 22 percent of the total analytic cases seen at NorthShore. The next most frequent cancers seen were: lung (11 percent), prostate (10 percent), and colon and melanoma (5 percent each). These top five sites represent 53 percent of all newly diagnosed cases.

Distribution by AJCC Stage for the Top Five Sites seen at NorthShore

Cancer diagnoses are broken down into five stages. Each stage represents how far the cancer cells have spread. Eighty-six percent of our breast cancers were diagnosed at an early stage (stages 0, 1 and 2), reflecting the national (83 percent) trend toward early detection. Thirty-eight percent of our lung cancers (national 28 percent), 80 percent of our prostate cancers (national: 80 percent), 55 percent of our colon cancers (national: 49 percent) and 84 percent of our melanoma cancers (national: 71 percent) were also diagnosed with early stage disease. In each of the top sites seen at NorthShore, detection at an early stage was significantly higher or equal to that seen nationally. National data supplied by the 2010 NCDB, Commission on Cancer, ACoS Benchmark Reports (2008 data); data for NorthShore is from diagnosis year 2009. See Table 2 on page 21.

Survival by Stage at Diagnosis

Stage at diagnosis also predicts the patient's survival rate, or the percentage of people who will survive for five years after the cancer diagnosis. Based on cases diagnosed in 2003 and submitted to the National Cancer Data Base (NCDB) overall survival rates at NorthShore for the top five sites compare favorably to those seen nationally. For breast cancer our overall five-year survival rate is 91 percent (national: 85 percent). Longer or equivalent overall survival rates are seen for the remaining top four sites as well. See graph for colon and rectum on page 4, breast on page 8, prostate on page 13, lung on page 14 and melanoma on page 17.

Source: 2010 NCDB, Commission on Cancer, Survival Reports

**TABLE 1: INCIDENCE OF CANCER—
2008 DATA SUMMARY**

Primary Site	Analytic	Non-Analytic	Total	Percent
Oral Cavity and Pharynx	61	10	71	1.9%
Lip	1	0	1	0.0%
Tongue	19	3	22	0.6%
Salivary Glands	10	2	12	0.3%
Gum and Other Mouth	8	2	10	0.3%
Nasopharynx	2	0	2	0.1%
Tonsil	13	0	13	0.3%
Oropharynx	6	2	8	0.2%
Hypopharynx	2	1	3	0.1%
Digestive System	526	73	599	15.7%
Esophagus	34	7	41	1.1%
Stomach	49	6	55	1.4%
Small Intestine	10	2	12	0.3%
Colon Excluding Rectum	176	24	200	5.3%
Rectum & Rectosigmoid	85	10	95	2.5%
Anus, Anal Canal & Anorectum	7	0	7	0.2%
Liver & Intrahepatic Bile Duct	33	6	39	1.0%
Intrahepatic Bile Duct	1	3	4	0.1%
Gallbladder	5	2	7	0.2%
Other Biliary	18	0	18	0.5%
Pancreas	101	13	114	3.0%
Retroperitoneum	4	3	7	0.2%
Peritoneum, Omentum & Mesentery	3	0	3	0.1%
Other Digestive Organs	1	0	1	0.0%
Respiratory System	369	27	396	10.4%
Nose, Nasal Cavity and Middle Ear	3	0	3	0.1%
Larynx	13	2	15	0.4%
Lung & Bronchus	353	24	377	9.9%
Pleura	0	1	1	0.0%
Bones and Joints	3	1	4	0.1%
Soft Tissue	19	2	21	0.6%
Skin excluding Basal and Squamous	168	29	197	5.2%
Melanoma – Skin	161	28	189	5.0%
Other Non-epithelial Skin	7	1	8	0.2%
Breast	742	54	796	20.9%
Female Genital System	161	26	187	4.9%
Uterus	111	10	121	3.2%
Ovary	34	7	41	1.1%
Vagina	6	3	9	0.2%
Vulva	8	6	14	0.4%
Other Female Genital Organs	2	0	2	0.1%
Male Genital System	345	99	444	11.7%
Prostate	319	98	417	10.9%
Testis	26	0	26	0.7%
Urinary System	244	15	259	6.8%
Urinary Bladder	139	10	149	3.9%
Kidney & Renal Pelvis	102	5	107	2.8%
Ureter	2	0	2	0.1%
Other Urinary Organs	1	0	1	0.0%
Eye & Orbit	16	4	20	0.5%
Brain & Other Nervous System	158	41	199	5.2%
Brain	69	30	99	2.6%
Cranial Nerves & Other Nervous System	89	11	100	2.6%
Endocrine System	176	22	198	5.2%
Thyroid	113	10	123	3.2%
Other Endocrine including Thymus	63	12	75	2.0%
Lymphomas	158	19	177	4.6%
Nodal	97	14	111	2.9%
Extranodal	61	5	66	1.7%
Myeloma	33	6	39	1.0%
Leukemia	75	13	88	2.3%
Mesothelioma	5	1	6	0.2%
Kaposi Sarcoma	0	1	1	0.0%
Miscellaneous	85	23	108	2.8%
Total	3,344	465	3809	100.0%

**TABLE 2: STAGE OF DIAGNOSIS—
2008/2009 DATA**

Comparison of National Cancer Data Base (NCDB) to NorthShore Data

Breast	NorthShore (n = 742) (%) 2009	NCDB (n = 220,058) (%) 2008*
Stage		
0	24.5%	20.4%
I	37.5%	37.6%
II	24.3%	24.5%
III	9.4%	8.8%
IV	2.4%	3.7%
NA	0.1%	0.1%
Unknown	1.8%	4.9%
Total	100%	100%

Lung	NorthShore (n = 353) (%) 2009	NCDB (n = 167,604) (%) 2008*
Stage		
0		0.2%
I	30.0%	22.1%
II	8.2%	5.6%
III	28.0%	23.2%
IV	28.9%	39.0%
NA	2.5%	0.2%
Unknown	2.3%	9.5%
Total	100%	100%

Prostate	NorthShore (n = 319) (%) 2009	NCDB (n = 148,832) (%) 2008*
Stage		
0		0.0%
I		0.9%
II	79.6%	79.1%
III	11.9%	8.8%
IV	7.5%	5.1%
NA	0.3%	0.0%
Unknown	0.6%	6.1%
Total	100%	100%

Colon	NorthShore (n = 176) (%) 2009	NCDB (n = 80,270) (%) 2008*
Stage		
0	11.9%	6.4%
I	21.0%	19.5%
II	22.2%	23.1%
III	19.9%	22.8%
IV	18.2%	18.5%
NA	1.7%	0.1%
Unknown	5.1%	9.6%
Total	100%	100%

Melanoma	NorthShore (n = 161) (%) 2009	NCDB (n = 50,666) (%) 2008*
Stage		
0	18.6%	18.5%
I	59.6%	40.2%
II	6.2%	12.0%
III	9.9%	7.2%
IV	3.1%	3.8%
NA	0.0%	9.3%
Unknown	2.5%	9.0%
Total	100%	100%

Totals may not equal 100 due to rounding.

Source: 2010 NCDB, Commission on Cancer, Survival Reports.

* 2008 latest data from the NCDB